GCG and obesity disorder: RAY1225, a novel once-every-two-weeks GLP-1 and GLP receptor dual agonist, showed good tolerability and induced robust body weight reduction in Chinese adults with overweight and obesity (−13.05% compared with −3.62% in placebo) [53].